#USA #San Diego #Eli Lilly #FuturHealth #Foundayo

FuturHealth Innovates with Oral GLP-1 Treatment

In a significant advancement for the healthcare landscape, FuturHealth, a prominent clinical health platform, has taken the initiative to offer Foundayo, Eli Lilly's oral GLP-1 receptor agonist. This groundbreaking treatment option is part of a broader industry shift towards non-injectable alternatives, aimed at enhancing accessibility and patient comfort in managing health.

A New Era in Medication

Historically, GLP-1 medications have been synonymous with injectable treatments, which often deter patients due to the discomfort associated with needles. Dr. Michael Snyder, FuturHealth's in-house obesity specialist, expresses excitement about Foundayo, highlighting its potential to shift patient perceptions regarding GLP-1 care. Dr. Snyder remarks, "The key is to ensure that it is used within a structured program that supports nutrition, muscle preservation, and long-term health rather than focusing solely on weight loss."

FuturHealth's program has already aided over 400,000 individuals towards achieving healthier outcomes through its multifaceted approach, which incorporates medication as a component of a broader lifestyle enhancement strategy.

Clinical Success of Foundayo

Clinical studies have shown promising results for Foundayo, with participants experiencing an average body weight reduction of nearly 12%—approximately 27 pounds—over a 72-week period when administered at the maximum dosage. Additionally, improvements in blood sugar regulation were recorded, showcasing the medication’s effectiveness across various patient demographics. This data cements Foundayo’s position as an appealing option for patients seeking alternatives to traditional injectable therapies.

What sets Foundayo apart is not only its oral administration but also the convenience it offers; the once-daily pill can be taken without any food or water restrictions, greatly enhancing usability for patients.

Sustainable Health Solutions

FuturHealth is committed to making this transformative medication available across the United States, with prescriptions managed by affiliated healthcare providers and medications conveniently delivered to patients' homes. Their monthly membership package, starting at $198, includes access to clinical care, FDA-approved medications like Foundayo, and personalized guidance tailored to support sustainable health outcomes.

A core component of FuturHealth’s strategy emphasizes melding medication therapy with supportive clinical guidance in areas such as nutrition, exercise, and lifestyle adjustments. This holistic approach aims for lasting health improvements rather than temporary solutions.

Luke Mahoney, co-founder and CEO of FuturHealth, underscores the shift in the GLP-1 category, stating, "We’re entering a new phase where access, affordability, and usability are improving rapidly. Oral therapies like Foundayo are viewed as much friendlier than injectables, and we anticipate a more extensive patient engagement as these options hit the market at lower price points."

Conclusion

As FuturHealth continues to lead in personalized preventative healthcare, it embodies the future of treatment through innovative accessibility and a focus on comprehensive health solutions. The addition of Foundayo not only cements its status as a trailblazer in modern healthcare but also represents a crucial step in providing patients with the tools they need for long-term health success. For further details about FuturHealth's offerings, visit www.fh.co.

• ---

Important Safety Information: Foundayo™ is a prescription medication with risks, including a boxed warning for thyroid C-cell tumors and is not suitable for individuals with Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). For comprehensive prescribing information, consult healthcare providers or visit Foundayo's official site.